Management of T2DM Patient with Elevated ASCVD Risk

Statin Therapy Initiation

The American Diabetes Association recommends high-intensity statin therapy for patients with T2DM aged 40-75 years who have one or more additional ASCVD risk factors, with a goal of achieving ≥50% reduction in LDL cholesterol from baseline and an absolute LDL target of <70 mg/dL (1, 2)
High-intensity statin options include atorvastatin 40-80 mg daily and rosuvastatin 20-40 mg daily, with atorvastatin being preferred for cost-effectiveness (1, 2)
Meta-analyses demonstrate a 9% reduction in all-cause mortality and 13% reduction in vascular mortality for each 39 mg/dL reduction in LDL cholesterol in patients with diabetes (2)

If LDL cholesterol remains ≥70 mg/dL after 4-12 weeks on maximally tolerated high-intensity statin, add ezetimibe 10 mg daily, which provides an additional 15-25% LDL cholesterol reduction (1, 2, 3)
PCSK9 inhibitors can be considered if LDL cholesterol remains ≥70 mg/dL despite maximally tolerated statin plus ezetimibe, providing an additional 50-60% LDL cholesterol reduction (1, 4)

The American Diabetes Association strongly recommends adding an SGLT2 inhibitor, such as empagliflozin, canagliflozin, or dapagliflozin, regardless of glycemic control status, to reduce the risk of death and cardiovascular events in patients with T2DM and cardiovascular disease (4, 5)
GLP-1 receptor agonists, such as liraglutide, semaglutide, or dulaglutide, can be considered for additional cardiovascular risk reduction (4)

Recheck lipid panel 4-12 weeks after statin initiation or dose change to assess response and adherence, and monitor lipid panel annually once at goal (3)
If the patient is on insulin and an SGLT2 inhibitor is added, reduce total daily insulin dose by approximately 20% if HbA1c is well-controlled to prevent hypoglycemia (5)

Do not use only the 10-year ASCVD risk to justify moderate-intensity statin therapy, as the presence of T2DM itself plus the elevated 30-year risk qualifies the patient for high-intensity therapy under current guidelines (1, 2)
If statin-related side effects occur, try alternative statins or lower doses rather than discontinuing entirely, and consider ezetimibe 10 mg daily as first-line alternative therapy if true statin intolerance is confirmed (2, 4)